Doctor details two new hepatitis C drugs

December 20, 2013 by Marie Mccullough

In the last three weeks, the Food and Drug Administration has approved two new drugs that are expected to dramatically improve treatment of chronic hepatitis C, a liver-damaging viral infection that afflicts more than 3.2 million Americans.

Sovaldi (sofosbuvir), made by Gilead, and Olysio (simeprevir), made by Janssen Therapeutics, could improve cure rates while reducing serious .

Jonathan M. Fenkel, a transplant hepatologist who directs Thomas Jefferson University's Hepatitis C Center, answered questions about the disease and the new drugs.

Question: How do you get hepatitis C and what does it do to the liver?

Fenkel: Hepatitis C is primarily a blood-borne infection, acquired through a contaminated blood transfusion, injection drug use, contaminated tattoo ink or needles, or accidental needlestick exposures. More than half of those infected with hep C in the U.S. are unaware they have it.

Because two-thirds of them are baby boomers - born between 1945 and 1965 - the Centers for Disease Control and Prevention recently recommended a hep C test for anyone born in those years.

Although a minority of people can spontaneously clear the infection without treatment, more than 80 percent develop chronic infection that can lead to cirrhosis, liver failure, and . Hep C-related liver failure is the most common reason for needing a liver transplant in the U.S.

Q: Until now, what was the standard treatment regimen, and how safe and effective was it?

A: The standard regimen included a combination of an injectable medication, pegylated interferon, and a pill, . Treatment could take 24 to 48 weeks, depending on the genotype of hepatitis C. (There are at least six types of hepatitis C, called genotypes, that can be thought of like strains of the flu virus.) The chance of a cure ranged from 30 percent to 80 percent, depending on genotype and other factors like prior treatment. However, side effects are nearly universal and include fatigue, flulike symptoms, rash, depression, nausea, and diarrhea.

In 2011, the FDA approved the antiviral agents Victrelis (boceprevir) and Incivek (telaprevir) for patients with genotype 1. Taking one of these medications along with interferon and ribavirin doubled response rates and shortened treatment for some patients. But severe side effects with this triple therapy were common, patients had to take up to 12 additional pills daily, and patients with other genotypes were not eligible to take these new antivirals.

Q: How do the new drugs, Sovaldi and Olysio, work?

A: Both interfere with the hepatitis C virus' ability to replicate or grow in the body. Olysio is a protease inhibitor, like Incivek and Victrelis, but is just one pill a day. Although it still must be combined with ribavirin and interferon, most patients end treatment in 24 weeks. Sovaldi, the first polymerase inhibitor for hep C, is also taken with ribavirin and, for some patients, with interferon. Treatment is as short as 12 weeks. And for the first time, genotype 2 and 3 patients can have an interferon-free therapy by taking Sovaldi with ribavirin.

Q: What are the side effects of the new drugs?

A: These drugs are far easier to tolerate than interferon and ribavirin. Fatigue, headache, and mild rash were among the reported problems, but few patients in the clinical trials stopped treatment due to side effects or adverse events.

Q: How are the new drugs expected to improve cure rates?

A: Cure rates are about 90 percent for regimens containing Sovaldi, and 80 percent for many regimens containing Olysio. Patients without underlying cirrhosis or being treated for the first time do best.

Q: The AIDS Healthcare Foundation and some other groups have expressed concerns about the costs of the . How expensive are they?

A: Sovaldi is reported to be $1,000 per day, or up to $84,000 for full treatment in genotype 1. Olysio's reported cost is nearly $800 a day, or $66,000 for full treatment. This is in addition to the cost of ribavirin or interferon, or both.

However, these prices are on a par with the costs of telaprevir or boceprevir, which payers have been covering. Also, the chance of cure is higher now, which could reduce the future costs associated with cirrhosis, , liver cancer, and liver transplantation. Still, I can definitely see cost being a barrier for some patients.

Q: Is this just the beginning of better treatments?

A: Yes. More than 20 drugs for hepatitis C may apply for FDA approval in the next five years, and even more are in the pipeline. I predict that in five years, treatment will be combined in one daily pill, taken for 12 weeks or less, with a cure rate of more than 95 percent.

Q: What about the prospects for a vaccine?

A: Unlike hepatitis A or B, hepatitis C has no antibody for potential preventive vaccine to target. But successfully treating who are chronically infected will decrease the worldwide reservoir of the C virus and decrease the need for a preventive vaccine.

Explore further: FDA approves new treatment for hepatitis C infection

Related Stories

FDA approves new treatment for hepatitis C infection

November 25, 2013
(HealthDay)—The U.S. Food and Drug Administration has approved a new drug for chronic hepatitis C infection that some experts hope will cut down on side effects from current therapies.

US approves breakthrough hepatitis C drug (Update)

December 6, 2013
U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.

New drug combination offers hope to patients with currently untreatable Hepatitis C

November 5, 2013
Hepatitis C is a viral infection which, if left untreated, can lead to severe and potentially fatal liver damage. Existing treatments consist of a combination of drugs, usually ribavirin, pegylated interferon and a protease ...

More drugs show promise in fighting hepatitis C

August 15, 2013
(HealthDay)—An experimental drug duo may cure some cases of the liver disease hepatitis C, without the severe side effects of standard therapy, a new clinical trial suggests.

Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant

October 31, 2013
New drug therapies offer promise to some hepatitis C sufferers whose transplanted livers are threated by a recurrence of the disease, including some patients who have had no treatment options.

US panel backs Gilead Sciences' hepatitis C drug (Update)

October 23, 2013
U.S. Food and Drug Administration advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions infected with the liver-destroying virus.

Recommended for you

Don't hold your nose and close your mouth when you sneeze, doctors warn

January 15, 2018
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors in the journal BMJ Case Reports.

New antifungal provides hope in fight against superbugs

January 12, 2018
Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant ...

Dengue takes low and slow approach to replication

January 11, 2018
A new study reveals how dengue virus manages to reproduce itself in an infected person without triggering the body's normal defenses. Duke researchers report that dengue pulls off this hoax by co-opting a specialized structure ...

Different strains of same bacteria trigger widely varying immune responses

January 11, 2018
Genetic differences between different strains of the same pathogenic bacterial species appear to result in widely varying immune system responses, according to new research published in PLOS Pathogens.

Human protein may aid neuron invasion by virus that causes hand, foot, and mouth disease

January 11, 2018
A human protein known as prohibitin may play a significant role in infection of the nervous system by EV71, one of several viruses that can cause hand, foot, and mouth disease. Issac Too of the National University of Singapore ...

Untangling how Epstein-Barr virus infects cells

January 11, 2018
A team led by scientists at Northwestern Medicine has discovered a new epithelial receptor for Epstein-Barr virus, according to a study published recently in Nature Microbiology.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.